GSK

GSK, a major UK-based pharmaceutical company, is currently in the news for several key developments. They are expanding their portfolio by acquiring RAPT, a Californian biotech firm, for $2.2 billion, gaining access to a drug targeting severe food allergies. GSK is also involved in the fight against antibiotic resistance, as new treatments for drug-resistant gonorrhea are being hailed as a potential turning point. However, the broader pipeline of new drugs to combat superbugs is reportedly shrinking, posing a challenge for the industry. GSK operates a high-biosecurity laboratory in Spain, dedicated to researching and combating dangerous viruses. Luke Miels recently took over as CEO. These activities highlight GSK's commitment to addressing critical health challenges and expanding its market presence, while also navigating the complexities of drug development and global health threats.